alirocumab + fenofibrate

**Alirocumab + fenofibrate** is a combination of two lipid-lowering pharmaceuticals: - **Alirocumab** is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (**PCSK9**), resulting in increased low-density lipoprotein receptor (**LDLR**) expression on hepatocytes and enhanced clearance of low-density lipoprotein cholesterol (**LDL-C**) from the blood[1][2][4]. - **Fenofibrate** is a fibric acid derivative (fibrate) that activates peroxisome proliferator-activated receptor alpha (**PPAR-alpha**), leading to increased expression of genes involved in lipid metabolism, which primarily lowers serum triglycerides and may moderately increase high-density lipoprotein cholesterol (**HDL-C**)[3]. This combination may be considered or studied in patients with mixed dyslipidemia or persistent hypercholesterolemia and hypertriglyceridemia not fully controlled by statins alone[3]. Both agents have different mechanisms, allowing for broader lipid profile improvement.